These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 25065702)
1. Sirolimus plus calcineurin inhibitors and methotrexate: is more necessarily better? William BM; de Lima M Leuk Lymphoma; 2015 Mar; 56(3):555-6. PubMed ID: 25065702 [No Abstract] [Full Text] [Related]
2. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. Ceberio I; Devlin SM; Sauter C; Barker JN; Castro-Malaspina H; Giralt S; Ponce DM; Lechner L; Maloy MA; Goldberg JD; Perales MA Leuk Lymphoma; 2015 Mar; 56(3):663-70. PubMed ID: 24913499 [TBL] [Abstract][Full Text] [Related]
3. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Pidala J; Kim J; Alsina M; Ayala E; Betts BC; Fernandez HF; Field T; Jim H; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C Haematologica; 2015 Jul; 100(7):970-7. PubMed ID: 25840599 [TBL] [Abstract][Full Text] [Related]
4. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925 [TBL] [Abstract][Full Text] [Related]
5. GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study. Parody R; López-Corral L; Lopez-Godino O; Martinez C; Martino R; Solano C; Barba P; Caballero D; García-Cadenas I; Piñana JL; Marquez-Malaver FJ; Vazquez L; Esquirol A; Boluda JC; Sanchez-Guijo F; Pérez-Simon JA Bone Marrow Transplant; 2016 Nov; 51(11):1524-1526. PubMed ID: 27295268 [No Abstract] [Full Text] [Related]
7. Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Khaled SK; Palmer JM; Herzog J; Stiller T; Tsai NC; Senitzer D; Liu X; Thomas SH; Shayani S; Weitzel J; Forman SJ; Nakamura R Biol Blood Marrow Transplant; 2016 Feb; 22(2):268-276. PubMed ID: 26325438 [TBL] [Abstract][Full Text] [Related]
8. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Pidala J; Kim J; Jim H; Kharfan-Dabaja MA; Nishihori T; Fernandez HF; Tomblyn M; Perez L; Perkins J; Xu M; Janssen WE; Veerapathran A; Betts BC; Locke FL; Ayala E; Field T; Ochoa L; Alsina M; Anasetti C Haematologica; 2012 Dec; 97(12):1882-9. PubMed ID: 22689677 [TBL] [Abstract][Full Text] [Related]
9. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016 [TBL] [Abstract][Full Text] [Related]
10. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. Cutler C; Antin JH Curr Opin Hematol; 2010 Nov; 17(6):500-4. PubMed ID: 20717025 [TBL] [Abstract][Full Text] [Related]
11. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856 [TBL] [Abstract][Full Text] [Related]
12. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Nelson R; Shapiro JF; Perkins JB; Kim J; Nishihori T; Pidala J; Ayala E; Locke FL; Field T; Mishra A; Riches M; Betts B; Perez L; Yue B; Ochoa-Bayona JL; Alsina M; Fernandez H; Anasetti C; Kharfan-Dabaja MA Bone Marrow Transplant; 2015 Nov; 50(11):1487-9. PubMed ID: 26301969 [No Abstract] [Full Text] [Related]
13. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745 [TBL] [Abstract][Full Text] [Related]
14. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Furlong T; Kiem HP; Appelbaum FR; Carpenter PA; Deeg HJ; Doney K; Flowers ME; Mielcarek M; Nash RA; Storb R; Martin PJ Biol Blood Marrow Transplant; 2008 May; 14(5):531-7. PubMed ID: 18410895 [TBL] [Abstract][Full Text] [Related]
15. A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. Piñana JL; Perez-Pitarch A; Garcia-Cadenas I; Barba P; Hernandez-Boluda JC; Esquirol A; Fox ML; Terol MJ; Queraltó JM; Vima J; Valcarcel D; Ferriols-Lisart R; Sierra J; Solano C; Martino R Biol Blood Marrow Transplant; 2017 Jul; 23(7):1177-1185. PubMed ID: 28396159 [TBL] [Abstract][Full Text] [Related]
16. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation. Kiel PJ; Vargo CA; Patel GP; Rosenbeck LL; Srivastava S Pharmacotherapy; 2012 May; 32(5):441-5. PubMed ID: 22499411 [TBL] [Abstract][Full Text] [Related]
17. [Progresses in studies on allogeneic hematopoietic stem cell transplantation in children with acquired severe aplastic anemia]. Liu TF; Zhu XF Zhonghua Er Ke Za Zhi; 2013 May; 51(5):345-8. PubMed ID: 23941840 [No Abstract] [Full Text] [Related]
18. [Familial hemophagocytic lymphohistiocytosis with the MUNC13-4 mutation after unrelated hematopoietic stem cell transplantation: a case report]. Tang XF; Luan Z; Wu NH; Zhang B; Wang K Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):944-5. PubMed ID: 24495769 [No Abstract] [Full Text] [Related]